Acamprosate Efficacy in Alcohol-Dependent Patients: Summary of Results from Three Pivotal Trials

REFERENCES

• Grant B F, Dawson D A, Stinson F S, Chou S P, Dufour M C, Pickering R P. The 12-month prevalence and trends in DSM-IV alcohol abuse and dependence: United States, 1991–1992 and 2001–2002. Drug Alcohol Depend. 2004; 74: 223–234
   PubMed Web of Science ®Google Scholar
• Chase V, Neild R, Sadler C W, Batey R G. The medical complications of alcohol use: understanding mechanisms to improve management. Drug Alcohol Rev. 2005; 24: 253–265
   PubMed Web of Science ®Google Scholar
• Garbutt J C, West S L, Carey T S, Lohr K N, Crews F T. Pharmacological treatment of alcohol dependence: A review of the evidence. JAMA. 1999; 281: 1318–1325
   PubMed Web of Science ®Google Scholar
• Harwood H. Updating Estimates of the Economic Costs of Alcohol Abuse in the United States: Estimates, Update Methods, and Data. US Department of Health and Human Services, Rockville, Md. 2000, Report prepared by The Lewin Group for the National Institute on Alcohol Abuse and Alcoholism
   Google Scholar
• Cohen E, Feinn R, Arias A, Kranzler H R. Alcohol treatment utilization: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Drug Alcohol Depend 2007; 86: 214–221
   PubMed Web of Science ®Google Scholar
• Mark T L, Kranzler H R, Song X. Understanding U.S. addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend. 2003; 71: 219–228
   PubMed Web of Science ®Google Scholar
• Kessler R C, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289: 3095–3105
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus S C, Druss B, Elinson L, Tanielian T, Pincus H A. National trends in the outpatient treatment of depression. JAMA. 2002; 287: 203–209
   PubMed Web of Science ®Google Scholar
• Friedmann P D, McCullough D, Chin M H, Saitz R. Screening and intervention for alcohol problems. A national survey of primary care physicians and psychiatrists. J Gen Intern Med. 2000; 15: 84–91
   PubMed Web of Science ®Google Scholar
• Mark T L, Kranzler H R, Song X, Bransberger P, Poole V H, Crosse S. Physicians' opinions about medications to treat alcoholism. Addiction. 2003; 98: 617–626
   PubMed Web of Science ®Google Scholar
• Anton R F, Swift R M. Current pharmacotherapies of alcoholism: A U.S. perspective. Am J Addict 2003; 12: S53–S68, (Suppl. 1)
   Web of Science ®Google Scholar
• Finney J W, Hahn A C, Moos R H. The effectiveness of inpatient and outpatient treatment for alcohol abuse: The need to focus on mediators and moderators of setting effects. Addiction. 1996; 91: 1773–1796
   PubMed Web of Science ®Google Scholar
• Friedmann P D, Saitz R, Samet J H. Management of adults recovering from alcohol or other drug problems: Relapse prevention in primary care. JAMA. 1998; 279: 1227–1231
   PubMed Web of Science ®Google Scholar
• O'Brien C P, McLellan A T. Addiction medicine. JAMA. 1997; 277: 1840–1841
   PubMed Web of Science ®Google Scholar
• Swift R M. Drug therapy for alcohol dependence. N Engl J Med. 1999; 340: 1482–1490
   PubMed Web of Science ®Google Scholar
• De Witte P. Imbalance between neuroexcitatory and neuroinhibitory amino acids causes craving for ethanol. Addict Behav. 2004; 29: 1325–1339
   PubMed Web of Science ®Google Scholar
• Kumari M, Ticku M K. Regulation of NMDA receptors by ethanol. Prog Drug Res. 2000; 54: 152–189
   PubMedGoogle Scholar
• Littleton J. Acamprosate in alcohol dependence: How does it work?. Addiction. 1995; 90: 1179–1188
   PubMed Web of Science ®Google Scholar
• De Witte P, Littleton J, Parot P, Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs. 2005; 19: 517–537
   PubMed Web of Science ®Google Scholar
• Mann K, Lehert P, Morgan M Y. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis. Alcohol Clin Exp Res. 2004; 28: 51–63
   PubMed Web of Science ®Google Scholar
• Mason B J, Goodman A M, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res. 2006; 40: 383–393
   PubMed Web of Science ®Google Scholar
• Bouza C, Magro A, Munoz A, Amate J M. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: A systematic review. Addiction. 2004; 99: 811–828
   PubMed Web of Science ®Google Scholar
• Anton R F, O'Malley S S, Ciraulo D A, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study—a randomized controlled trial. JAMA. 2006; 295: 2003–2017
   PubMed Web of Science ®Google Scholar
• Morley K C, Teesson M, Reid S C, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006; 101: 1451–1462
   PubMed Web of Science ®Google Scholar
• Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997; 171: 73–77
   PubMed Web of Science ®Google Scholar
• Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996; 53: 673–680
   PubMed Web of Science ®Google Scholar
• Paille F M, Guelfi J D, Perkins A C, Royer R J, Steru L, Parot P. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995; 30: 239–247
   PubMed Web of Science ®Google Scholar
• Arrange Psycheatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd ed., revised. American Psychiatric Association, Washington, DC 1987
   Google Scholar
• Rosenberg H, Davis L A. Acceptance of moderate drinking by alcohol treatment services in the United States. J Stud Alcohol. 1994; 55: 167–172
   PubMed Web of Science ®Google Scholar
• Namkoong K, Lee B O, Lee P G, Choi M J, Lee E. Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003; 38: 135–141
   PubMed Web of Science ®Google Scholar
• Chick J, Howlett H, Morgan M Y, Ritson B. United Kingdom Multicentre Acamprosate Study (UKMAS): A six-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000; 35: 176–187
   PubMed Web of Science ®Google Scholar
• Mason B J. Acamprosate for alcohol dependence: An update for the clinician. Focus 2006; IV: 505–511
   Google Scholar
• Johnson B A, Roache J D, Javors M A, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA. 2000; 284: 963–971
   PubMed Web of Science ®Google Scholar
• Kranzler H R, Burleson J A, Brown J, Babor T F. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res. 1996; 20: 1534–1541
   PubMed Web of Science ®Google Scholar
• Johnson B A. An overview of the development of medications including novel anticonvulsants for the treatment of alcohol dependence. Expert Opin Pharmacother. 2004; 5: 1943–1955
   PubMed Web of Science ®Google Scholar